BioLife Solutions, Inc. (NASDAQ:BLFS) had its price target increased by Maxim Group from $7.00 to $8.00 in a research report sent to investors on Friday morning, MarketBeat Ratings reports. Maxim Group currently has a buy rating on the medical equipment provider’s stock.

Shares of BioLife Solutions (BLFS) traded up $0.30 during trading hours on Friday, hitting $6.21. 173,700 shares of the company’s stock were exchanged, compared to its average volume of 107,127. BioLife Solutions has a 52 week low of $1.50 and a 52 week high of $7.53.

BioLife Solutions (NASDAQ:BLFS) last issued its earnings results on Thursday, November 9th. The medical equipment provider reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.03. The company had revenue of $2.96 million during the quarter, compared to analyst estimates of $2.60 million. BioLife Solutions had a negative net margin of 52.10% and a negative return on equity of 49.92%. equities research analysts expect that BioLife Solutions will post -0.24 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “BioLife Solutions, Inc. (BLFS) Price Target Raised to $8.00 at Maxim Group” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.watchlistnews.com/biolife-solutions-inc-blfs-price-target-raised-to-8-00-at-maxim-group/1702559.html.

Hedge funds have recently added to or reduced their stakes in the stock. Essex Investment Management Co. LLC acquired a new stake in shares of BioLife Solutions in the 3rd quarter valued at $484,000. EAM Investors LLC acquired a new stake in shares of BioLife Solutions in the 3rd quarter valued at $555,000. Finally, Granite Investment Partners LLC acquired a new stake in shares of BioLife Solutions in the 3rd quarter valued at $1,205,000. 3.27% of the stock is owned by institutional investors and hedge funds.

BioLife Solutions Company Profile

BioLife Solutions, Inc (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers.

Receive News & Ratings for BioLife Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.